CD8+ mycosis fungoides: A low-grade lymphoproliferative disorder - 12/08/17
Abstract |
Background |
The prognosis of the CD8+ subtype of mycosis fungoides (MF) is controversial. Although most authors believe that determining the presence of this cell surface antigen has no prognostic value, others have observed a more indolent course for CD8+ MF compared with CD4+ MF.
Objectives |
To review the cases of CD8+ MF in the pediatric and adult populations seen at our institution.
Methods |
This is a retrospective review of clinical and pathologic data. Age, stage at presentation, and outcomes of patients at our institution were compared with those of 2 large MF cohorts that predominantly were CD4+ from the relevant literature.
Results |
Sixty-seven patients of a median age of 46 years were included. A higher frequency of early-stage disease was observed for CD8+ MF patients at diagnosis when compared with other cohorts, including 31 (47%) patients with stage IA, 33 (50%) with stage IB, and 2 (3%) with stage IIB (P = .001, P = .001, and P = .002, respectively). With a median follow-up (5.5 years, range 0.2-21 years) similar to other cohorts, a higher rate of complete remission was achieved (65.5%, P = .001), and a lower rate of progression was observed (P = .004).
Limitations |
This is a retrospective review.
Conclusion |
Our experience with CD8+ MF confirms a more indolent course of disease with this MF variant. Our results warrant a conservative treatment approach limited to skin-directed therapies and observation in most patients.
Le texte complet de cet article est disponible en PDF.Key words : CD8+ phenotype, cutaneous lymphoma, lymphoproliferative disorder, mycosis fungoides, prognosis, skin directed-therapies
Abbreviations used : BSA, CTCL, HL, LyP, MF, PCAETCL, PCGDTCL, SLE, TCR, TIA-1
Plan
Funding sources: None. |
|
Conflicts of interest: None declared. |
|
Reprints not available from the authors. |
Vol 77 - N° 3
P. 489-496 - septembre 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?